Attachmmt II - F^e 5 
9212-035“ 
9212-036“ 
9303-037“ 
9303-038 
9303-039 
9303-040 
9303-041* 
9303-042* 
9306-043* 
(T) Wilson, James M.; University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, and Richard H. ^ 
Simon; University of Michigan Medical Center, Ann Arbor, Michigan; Gene Therapy of Cystic Fibrosis 
Lung Diseases Using El Deleted Adenoviruses: A Phase I Trial. 
RAC Approval: 12-3-92/NIH Approval: 8-26-93 
Minor Modification: 8-17-93 
Minor Modification: 8-26-93 
Minor Modification: 8-31-94 
(T) Welsh, Michael J.; Howard Hughes Medical Institute, Iowa City, Iowa, and Smith, Alan E.; Genzyme : j 
Corporation, Framingham, Massachusetts; Cystic Fibrosis Gene Therapy Using an Adenovirus Vector. In 
Vivo Safety and Efficacy in Nasal Epithelium. 
RAC Approval: 12-4-92/NIH Approval: 4-16-93 
Minor Modification: 10-18-93 ‘j 
(T) Culver, Kenneth W.; Iowa Methodist Medical Center, Des Moines, Iowa, Van Gilder, John C.; University 
of Iowa, Iowa City, Iowa, Berger, Mitchel; University of California, San Francisco, California, and Prados, 
Michael; University of Washington, Seattle, Washington; Gene Therapy for the Treatment of Recurrent * 
Glioblastoma Multiforme with In Vivo Tumor Transduction with the Herpes Simplex Thymidine Kinase 
Gene/Ganciclovir System. 
RAC Approval: 3-1-93/NIH Approval: 4-16-93 
Minor Modification: 7-13-94 
(M) Heslop, Helen E.; Brenner, Malcolm FL; and Rooney, Cliona; St. Jude Children’s Research Hospital, 
Memphis, Tennessee; Administration of Neomycin Resistance Gene Marked EBV Specific Cytotoxic T 
Lymphocytes to Recipients of Mismatched-Related or Phenotypically Similar Unrelated Donor Marrow Grafts. 
RAC Approval: 3-2-93/NIH Approval: 4-16-93 
Minor Modification: 8-31-94 
(M) Brenner, Malcolm K.; Krance, Robert; Heslop, Helen E.; Santana, Victor; and Ihle, James; St. Jude 
Children’s Research Hospital, Memphis, Tennessee; Assessment of the Efficacy of Purging by Using Gene- 
Marked Autologous Marrow Transplantation for Children with Acute Myelogenous Leukemia in First 
Complete Remission. 
RAC Approval: 3-2-93/NIH Approval: 4-16-93 
(T) Simons, Jonathan; Johns Hopkins Oncology Center, Baltimore, Maryland; Phase I Study of Non-Replicating 
Autologous Tumor Cell Injections Using Cells Prepared With or Without Granulocyte-Macrophage Colony 
Stimulating Factor Gene Transduction in Patients with Metastatic Renal Cell Carcinoma. 
RAC Approval: 3-1-93/NIH Approval: 12-2-93 
(T) Wilmott, Robert W. and Whitsett, Jeffrey, Children’s Hospital Medical Center, Cincinnati, Ohio, and 
Trapnell, Bruce; Genetic Therapy, Inc., Gaithersburg, Maryland; A Phase I Study of Gene Therapy of Cystic 
Fibrosis Utilizing a Replication Deficient Recombinant Adenovirus Vector to Deliver the Human Cystic 
Fibrosis Transmembrane Conductance Regulator cDNA to the Airways. 
RAC Approval: 3-2-93/NIH Approval: 4-16-93 
Minor Modification: 8-31-94 
(T) Boucher, Richard C. and Knowles, Michael R.; University of North Carolina, Chapel Hill, North Carolina; 
Gene Therapy for Cystic Fibrosis Using El Deleted Adenovirus: A Phase I Trial in the Nasal Cavity. 
RAC Approval: 3-2-93/NIH Approval: 10-7-93 
Minor Modification: 2-17-94 
(T) Seigler, Hilliard F.; Duke University Medical Center, Durham, North Carolina; and Merchant, Bruce; 
Viagene, Inc., San Diego, California; A Phase I Trial of Human Gamma Interferon-Transduced Autologous 
Tumor Cells in Patients With Disseminated Malignant Melanoma. 
RAC Approval: 6-7-93/NIH Approval: 9-3-93 
Minor Modification: 7-11-94 
[96] 
Recombinant DNA Research, Volume 20 
